Ptc Therapeutics (PTCT) EBITDA Margin (2012 - 2026)

Ptc Therapeutics' EBITDA Margin history runs 15 years deep, the most recent figure standing at 16.5% for Q1 2026.

• In Q1 2026, EBITDA Margin fell 6600.0% year-over-year to 16.5%; the TTM figure through Mar 2026 stood at 7.05% (down 5201.0% YoY), while the FY2025 annual figure was 50.09%, up 8760.0% from the prior year.
• EBITDA Margin was 16.5% for Q1 2026 at Ptc Therapeutics, up from 43.33% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 82.5% in Q1 2025 to a low of 119.67% in Q4 2022.
• Historically, EBITDA Margin has averaged 35.16% across 5 years, with a median of 37.37% in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin jumped 12156 bps in 2023, then sank 7807 bps in 2024.
• A 5-year view of EBITDA Margin shows it stood at 119.67% in 2022, then surged by 102 bps to 1.9% in 2023, then plunged by 4119 bps to 76.18% in 2024, then surged by 43 bps to 43.33% in 2025, then soared by 138 bps to 16.5% in 2026.
• The last three EBITDA Margin figures came in at 16.5% (Q1 2026), 43.33% (Q4 2025), and 1.43% (Q3 2025), per Business Quant data.